AC
FATE icon

AXQ Capital’s Fate Therapeutics FATE Stock Holding History

AXQ Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8K Buy
+10,706
New +$13K ﹤0.01% 971
2024
Q2 		– Sell
-20,400
Closed -$150K – 536
2024
Q1 		$150K Buy
+20,400
New +$126K 0.04% 550
2023
Q2 		– Sell
-15,964
Closed -$91K – 390
2023
Q1 		$91K Sell
15,964
-52,175
-77% -$315K 0.04% 452
2022
Q4 		$688K Buy
+68,139
New +$1.28M 0.48% 65

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXQ Capital's FATE Position: Q1 2026 in Review

AXQ Capital opened a new position in Fate Therapeutics (FATE) in Q1 2026: 10,706 shares worth $12.8K. The stake represents ﹤0.01% of the portfolio and ranks #971 among its holdings. This is a return to the name: AXQ Capital previously reported a position in FATE as recently as Q1 2024.

AXQ Capital first reported a position in FATE in Q4 2022 and has held it in 4 quarters since. The position peaked at $688K in Q4 2022. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • AXQ Capital held 10,706 shares of Fate Therapeutics worth $12.8K as of Q1 2026.
  • Fate Therapeutics was a new AXQ Capital position in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of AXQ Capital's portfolio in Q1 2026, its #971 holding.
  • AXQ Capital first reported a position in Fate Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • AXQ Capital's Fate Therapeutics position peaked at $688K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.